BNP Paribas Asset Management
MYGN icon

BNP Paribas Asset Management’s Myriad Genetics MYGN Stock Holding History

BNP Paribas Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5K Buy
3,437
+1,577
+85% +$8.22K ﹤0.01% 2097
2025
Q4 		$11K Buy
1,860
+649
+54% +$4.71K ﹤0.01% 2123
2025
Q3 		$9K Hold
1,211
– – ﹤0.01% 1672
2025
Q2 		$6K Buy
+1,211
New +$7.15K ﹤0.01% 1947

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Asset Management's MYGN Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Myriad Genetics (MYGN) stake by 85% in Q1 2026, buying an estimated $8.22K and bringing the position to 3,437 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2097.

BNP Paribas Asset Management first reported a position in MYGN in Q2 2025 and has held it in 4 quarters since. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • BNP Paribas Asset Management held 3,437 shares of Myriad Genetics worth $15.5K as of Q1 2026.
  • BNP Paribas Asset Management bought 1,577 Myriad Genetics shares in Q1 2026, an estimated $8.22K.
  • Myriad Genetics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2097 holding.
  • BNP Paribas Asset Management first reported a position in Myriad Genetics in Q2 2025 and has held it in 4 quarters since.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.